About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Maryland | 19,983 Studies Near You | Clareo Health

Clinical Trials LocationsMaryland

Clinical Trials in Maryland

Discover 19,983 clinical trials near Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 12621-12640 of 19,983 trials

COMPLETEDNA6.0 miles

Measuring Single-Serving Grain Intake

NCT03783637

The primary objective of this study is to identify markers of a single meal of whole grain oat and whole grain wheat intake in humans.

Healthy Volunteers

USDA Beltsville Human Nutrition Research Center12 participantsStarted May 2019

Beltsville, Maryland, United States

COMPLETEDPhase 315 miles

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

NCT01919697

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

Chronic Idiopathic Constipation

Bausch Health Americas, Inc.2,370 participantsStarted Aug 2013

Birmingham, Alabama, United States • Dothan, Alabama, United States • Gulf Shores, Alabama, United States +217 more locations

Find Trials by Condition in Maryland

Breast Cancerin Maryland Lung Cancerin Maryland Prostate Cancerin Maryland Colorectal Cancerin Maryland Melanomain Maryland Leukemiain Maryland Lymphomain Maryland Pancreatic Cancerin Maryland Ovarian Cancerin Maryland Brain Cancerin Maryland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDNA17 miles

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

NCT02707406

The study is evaluating NEOX®CORD 1K, a cryopreserved human umbilical cord allograft. The purpose of the study is to evaluate the safety, incidence and rate of wound closure following application of the product compared to standard of care in the treatment of difficult to heal diabetic foot ulcers.

Diabetic Foot Ulcers

BioTissue Holdings, Inc124 participantsStarted Feb 2016

Carlsbad, California, United States • Castro Valley, California, United States • Fair Oaks, California, United States +19 more locations

COMPLETEDNA19 miles

Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery

NCT00952315

The investigators plan to compare three different devices that are used to break up large kidney stones during surgery for removal to see if one is faster or more efficient than the others.

Indiana Kidney Stone Institute270 participantsStarted Aug 2009

Phoenix, Arizona, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +7 more locations

COMPLETEDPhase 419 miles

Study of the Effectiveness of Ozurdex for the Control of Uveitis

NCT02049476

The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the treatment of active sight-threatening, noninfectious intermediate and/or posterior uveitis in which immunosuppressive drug therapy is indicated. Uveitis is an inflammation inside the eye. Uveitis can decrease patients' vision if it is not treated. The dexamethasone pellet is an implant filled with a corticosteroid medicine. This therapy is approved by the Food and Drug Administration (FDA) for the treatment of intermediate and/or posterior uveitis. In this study investigators want to see if using the implant together with systemic immunosuppressive drug therapy can result in lower ocular side effect profile but is effective enough to replace the use of high-dose systemic corticosteroids in the treatment of active intermediate and/or posterior uveitis. Knowing the effectiveness and safety of these treatments is important because the kinds of uveitis being studied usually need to be treated for many years. This information may help researchers understand uveitis better and may suggest ways of improving treatment. Adult patients with intermediate and/or posterior uveitis for which immunosuppressive drug therapy with high-dose corticosteroid is planned may join.

Uveitis, IntermediateUveitis, Posterior

Johns Hopkins University20 participantsStarted Jan 2014

Baltimore, Maryland, United States

COMPLETEDPhase 419 miles

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480

The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI relative to two metered dose inhalers (MDI), a GSK MDI and the AstraZeneca (AZ) MDI. It is a randomised, multi-centre, open-label, cross-over study comparing placebo ELLIPTA DPI with placebo MDI (GSK and AZ) to assess correct inhaler use. No active drug will be used in this study in order to prevent any drug-related effects. Approximately, 152 subjects will be randomized to receive ELLIPTA DPI inhaler and 152 will be randomized to receive one of the MDI inhalers, for use during the first period (P) (approximately 28 days). At Visit 2 (Day 28) all subjects previous receiving the ELLIPTA DPI will be randomized to receive one of the MDI inhalers and all subjects who received a MDI in the previous period will receive the ELLIPTA DPI for use during second period (approximately 28 days). Subjects will continue taking their asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period. ELLIPTA is a registered trademark of the GSK group of companies.

GlaxoSmithKline324 participantsStarted Aug 2016

Huntington Beach, California, United States • Aventura, Florida, United States • Clearwater, Florida, United States +17 more locations

COMPLETEDPhase 219 miles

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604

Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.

Peanut HypersensitivityFood HypersensitivityHypersensitivity+1 more

National Institute of Allergy and Infectious Diseases (NIAID)75 participantsStarted Sep 2013

Little Rock, Arkansas, United States • Denver, Colorado, United States • Baltimore, Maryland, United States +2 more locations

COMPLETEDPhase 228 miles

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

NCT01072175

This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts. In Part A, the effect of repeat doses of GSK1120212 on the pharmacokinetics of single dose GSK2118436 was investigated prior to evaluating combination regimens. In Part B, the range of tolerated dose combinations was identified using a dose-escalation procedure. In Part C, different dose combinations of GSK2118436 and GSK1120212 were evaluated, based on results from the dose escalation cohorts. In Part D, the pharmacokinetics and safety of GSK2118436 administered as HPMC capsules alone and in combination with GSK1120212 was evaluated.

Novartis Pharmaceuticals430 participantsStarted Mar 2010

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +12 more locations

COMPLETED31 miles

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

NCT03999281

Retrospective clinical study of 188 patients to examine effectiveness of human cryopreserved allograft in the treatment of diabetic foot ulcers and venous leg ulcers

Determine Effectiveness of Theraskin in the Treatment of DFU and VLU

Solsys Medical LLC188 participantsStarted Mar 2003

Fairfax, Virginia, United States

COMPLETEDNA107 miles

Radiofrequency Ablation in Treating Patients With Bone Metastases

NCT00026247

RATIONALE: Radiofrequency ablation may be effective in decreasing pain from bone metastases. PURPOSE: Phase I/II trial to study the effectiveness of radiofrequency ablation in decreasing pain in patients who have bone metastases.

Metastatic CancerPainUnspecified Adult Solid Tumor, Protocol Specific

American College of Radiology Imaging Network66 participantsStarted Nov 2001

Birmingham, Alabama, United States • Worcester, Massachusetts, United States • St Louis, Missouri, United States +5 more locations

COMPLETEDPhase 1107 miles

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02464670

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.

Inovio Pharmaceuticals240 participantsStarted May 2015

Miami, Florida, United States • Kansas City, Missouri, United States • Philadelphia, Pennsylvania, United States

TERMINATEDPhase 3115 miles

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906

The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40\_301 study \[NCT01931566\] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

Mild Cognitive Impairment Due to Alzheimer's Disease

Takeda40 participantsStarted Feb 2015

Phoenix, Arizona, United States • Sun City, Arizona, United States • San Diego, California, United States +40 more locations

COMPLETEDPhase 2172 miles

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551

The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).

Malignant Melanoma

Viralytics57 participantsStarted Dec 2011

La Jolla, California, United States • San Francisco, California, United States • Miami Beach, Florida, United States +7 more locations

COMPLETED187 miles

ATHENA: Natural History of Disease Study in Alport Syndrome Patients

NCT02136862

There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients. Patients with a confirmed diagnosis of Alport syndrome who have qualifying GFR will be considered for enrollment. The sequential sampling of subjects' urine and/or blood will allow an assessment of the rate of change of established clinical endpoints, such as GFR and/or the rate of change of other renal biomarkers (proteinuria and β-2 microglobulin) in subjects whose renal function is steadily declining. The identification of surrogate markers that track the decline of renal function and could correlate with time to end-stage renal disease (ESRD) is a key goal of the natural history study.

Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2

Genzyme, a Sanofi Company165 participantsStarted Sep 2014

San Diego, California, United States • Chicago, Illinois, United States • Minneapolis, Minnesota, United States +12 more locations

COMPLETEDPhase 1187 miles

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

NCT01966445

Human Epidermal Growth Factor Receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis. Up-regulation of HER3 expression and activity is also associated with resistance to multiple pathway inhibitors. GSK2849330, a monoclonal antibody targeting HER3, is a new agent for subjects whose tumors express HER3. This study is a phase I, first time in human, open-label, dose escalation study. The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2849330 in subjects with advanced HER3-positive solid tumors. The study will be conducted in two parts. Part 1 (Dose-Escalation Phase) will include dose escalation and PK/PD cohorts to evaluate safety, PK, and PD to guide selection of dose regimen(s) for Part 2. In Part 2 (Expansion Cohorts), up to 3 cohorts will be enrolled at the dose regimen(s) selected based on Part 1 data, to evaluate safety in a larger cohort of subjects at the recommended dose regimen and also to evaluate preliminary evidence of clinical benefit.

CancerNeoplasms

GlaxoSmithKline29 participantsStarted Nov 2013

Aurora, Colorado, United States • New York, New York, United States • Salt Lake City, Utah, United States +11 more locations

COMPLETEDPhase 3187 miles

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

NCT02377921

The primary objective of this study is to evaluate the effect of 6 g/day aceneuramic acid extended-release (Ace-ER) treatment of participants with GNEM on upper extremity muscle strength (upper extremity composite \[UEC\] score) as measured by dynamometry.

Hereditary Inclusion Body MyopathyDistal Myopathy With Rimmed VacuolesDistal Myopathy, Nonaka Type+1 more

Ultragenyx Pharmaceutical Inc89 participantsStarted May 2015

Irvine, California, United States • St Louis, Missouri, United States • New York, New York, United States +10 more locations

COMPLETEDPhase 3198 miles

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064

This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (\>/=) 2 centimeters (cm). The study was designed to evaluate the efficacy and safety of trastuzumab emtansine + pertuzumab (experimental arm; T-DM1 + P) versus chemotherapy, trastuzumab + pertuzumab (control arm; TCH + P). The study comprised a neoadjuvant treatment period, followed by surgery, and an adjuvant treatment period. Treatment can be stopped due to disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination.

Breast Neoplasms

Hoffmann-La Roche444 participantsStarted Jun 2014

Fullerton, California, United States • Los Angeles, California, United States • San Luis Obispo, California, United States +76 more locations

COMPLETEDNA337 miles

Two Daily Disposable Contact Lenses in Symptomatic Patients

NCT03628599

The purpose of this study is to evaluate the performance of DAILIES TOTAL1® and ACUVUE OASYS® 1-DAY and with respect to visual acuity in a symptomatic study population of monthly or bi-weekly replacement lens wearers.

Alcon Research39 participantsStarted Aug 2018

Bloomington, Illinois, United States • Pittsburg, Kansas, United States • Powell, Ohio, United States +1 more locations

COMPLETEDPhase 2/3377 miles

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

NCT01912716

It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas) after endoscopic retrograde cholangiopancreatography (ERCP) in high risk patients. However, the optimal dose required is not known. The purpose of this study is to determine whether a dose of 200 mg, administered as rectal suppositories, is more effective than the standard dose of 100 mg. An ERCP procedure is a scope procedure where a lighted tube with a camera is passed down the patient's throat and allows for evaluation of the bile duct and/or pancreatic duct. The most common side effect of this procedure is post-ERCP pancreatitis, or swelling of the pancreas. Some patients are at higher risk for this complication than others. Our hypothesis is to compare the efficacy of these two dose regimens (100 mg vs 200 mg) of prophylactic rectally-administered indomethacin on the frequency and severity of post-ERCP pancreatitis in high-risk patients.

Post-ERCP Pancreatitis

Indiana University1,037 participantsStarted Jul 2013

Indianapolis, Indiana, United States • Boston, Massachusetts, United States • Ann Arbor, Michigan, United States +3 more locations

COMPLETEDPhase 32437 miles

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT01741532

A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN. This investigator-initiated trial was funded by the European Commission's Seventh Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON consortium (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA Office of Orphan Products Development (OOPD) (Dr. Elliott Vichinsky).

Pantothenate Kinase-Associated Neurodegeneration

ApoPharma89 participantsStarted Dec 2012

Oakland, California, United States • Munich, Germany • Milan, Italy +1 more locations

PreviousPage 632 of 1000Next

in Maryland

Heart Diseasein Maryland